董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elizabeth Haanes | -- | Independent Director | 68 | 未披露 | 未持股 | 2025-08-01 |
| Michael Lee | 男 | Independent Director | 46 | 未披露 | 未持股 | 2025-08-01 |
| William Strohl | 男 | Independent Director | 72 | 2.95万美元 | 未持股 | 2025-08-01 |
| Christina Teng Topsoe | 女 | Independent Director | 44 | 未披露 | 未持股 | 2025-08-01 |
| Jakob Haldor Topsoe | 男 | Independent Director | 56 | 未披露 | 未持股 | 2025-08-01 |
| Mary Beth Harler | -- | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-08-01 |
| Felix J. Baker | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-01 |
| M. Kathleen Behrens | 女 | Independent Director | 72 | 未披露 | 未持股 | 2025-08-01 |
| Julie Hambleton | 女 | Independent Director | 67 | 2.95万美元 | 未持股 | 2025-08-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mary Beth Harler | -- | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-08-01 |
董事简历
中英对照 | 中文 | 英文- Elizabeth Haanes
-
Elizabeth Haanes自2019年8月起担任我们的知识产权Vice President。在加入我们之前，Haanes博士于2018年3月至2019年8月担任律师事务所Fisherbroyles，LLP知识产权组的合伙人，并于2014年1月至2018年3月担任律师事务所Thompson Coburn LLP知识产权组的合伙人。Haanes博士在密歇根大学（University of Michigan）获得生物学学士学位，在明尼苏达大学（University of Minnesota）获得微生物学博士学位，在科罗拉多大学（University of Colorado）获得法学博士学位。
Elizabeth Haanes has served as Vice President, Intellectual Property since August 2019. Prior to joining, Dr. Haanes served as a Partner in the intellectual property group of FisherBroyles, LLP, a law firm, from March 2018 to August 2019 and as a Partner in the intellectual property group of Thompson Coburn LLP, a law firm, from January 2014 to March 2018. Dr. Haanes received a B.S. in Biology from the University of Michigan, a Ph.D. in Microbiology from the University of Minnesota and a J.D. from the University of Colorado. - Elizabeth Haanes自2019年8月起担任我们的知识产权Vice President。在加入我们之前，Haanes博士于2018年3月至2019年8月担任律师事务所Fisherbroyles，LLP知识产权组的合伙人，并于2014年1月至2018年3月担任律师事务所Thompson Coburn LLP知识产权组的合伙人。Haanes博士在密歇根大学（University of Michigan）获得生物学学士学位，在明尼苏达大学（University of Minnesota）获得微生物学博士学位，在科罗拉多大学（University of Colorado）获得法学博士学位。
- Elizabeth Haanes has served as Vice President, Intellectual Property since August 2019. Prior to joining, Dr. Haanes served as a Partner in the intellectual property group of FisherBroyles, LLP, a law firm, from March 2018 to August 2019 and as a Partner in the intellectual property group of Thompson Coburn LLP, a law firm, from January 2014 to March 2018. Dr. Haanes received a B.S. in Biology from the University of Michigan, a Ph.D. in Microbiology from the University of Minnesota and a J.D. from the University of Colorado.
- Michael Lee
-
Michael Lee自2020年6月起担任董事会成员。Lee先生自2007年以来一直担任Redmile Group，LLC的联合创始人兼投资组合经理，该公司是一家总部位于旧金山和纽约的专注于医疗保健的投资公司。任职Redmile公司之前，他曾担任Steeple Capital公司、Welch Capital Partners公司和Prudential Equity Group的生物技术投资者。Lee先生目前在FateTherapeutics，Inc.和IGMBiosciences，Inc.的董事会任职。Lee先生在亚利桑那大学（University of Arizona）获得分子与细胞生物学学士学位。
Michael Lee has served as a member of Board since June 2020. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York, since 2007. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, Welch Capital Partners and Prudential Equity Group. Mr. Lee currently serves on the board of directors of Fate Therapeutics, Inc. and IGM Biosciences, Inc. Mr. Lee earned his B.S. in Molecular and Cellular Biology from the University of Arizona. - Michael Lee自2020年6月起担任董事会成员。Lee先生自2007年以来一直担任Redmile Group，LLC的联合创始人兼投资组合经理，该公司是一家总部位于旧金山和纽约的专注于医疗保健的投资公司。任职Redmile公司之前，他曾担任Steeple Capital公司、Welch Capital Partners公司和Prudential Equity Group的生物技术投资者。Lee先生目前在FateTherapeutics，Inc.和IGMBiosciences，Inc.的董事会任职。Lee先生在亚利桑那大学（University of Arizona）获得分子与细胞生物学学士学位。
- Michael Lee has served as a member of Board since June 2020. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York, since 2007. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, Welch Capital Partners and Prudential Equity Group. Mr. Lee currently serves on the board of directors of Fate Therapeutics, Inc. and IGM Biosciences, Inc. Mr. Lee earned his B.S. in Molecular and Cellular Biology from the University of Arizona.
- William Strohl
-
William Strohl自2018年8月以来一直担任我们的董事会成员。2016年8月，Strohl博士创立了Bistro Biotech Consulting，一家生物技术咨询公司，他还担任总裁。2016年2月至2016年8月，Strohl博士担任Janssen Biotherapeutics的Vice President和生物制剂研究员，Janssen Biotherapeutics是跨国医疗器械和制药公司强生公司Janssen研发部门的治疗性生物制剂组织，并于2013年10月至2016年2月担任其Vice President兼负责人。在此之前，从2008年4月到2013年10月，Strohl博士担任Janssen Biotherapeutics的抗体发现主管。Strohl博士还在默克制药公司（Merck）担任过各种职务，包括领导天然产物生物学和领先的生物制剂发现工作，并曾是俄亥俄州立大学（Ohio State University）微生物系和生物化学项目的教授。Strohl博士在中央密歇根大学（Central Michigan University）获得生物学学士学位，在路易斯安那州立大学（Louisiana State University）获得微生物学博士学位。
William Strohl has served as a member of board of directors since August 2018. In August 2016 Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016 Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013 Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University. - William Strohl自2018年8月以来一直担任我们的董事会成员。2016年8月，Strohl博士创立了Bistro Biotech Consulting，一家生物技术咨询公司，他还担任总裁。2016年2月至2016年8月，Strohl博士担任Janssen Biotherapeutics的Vice President和生物制剂研究员，Janssen Biotherapeutics是跨国医疗器械和制药公司强生公司Janssen研发部门的治疗性生物制剂组织，并于2013年10月至2016年2月担任其Vice President兼负责人。在此之前，从2008年4月到2013年10月，Strohl博士担任Janssen Biotherapeutics的抗体发现主管。Strohl博士还在默克制药公司（Merck）担任过各种职务，包括领导天然产物生物学和领先的生物制剂发现工作，并曾是俄亥俄州立大学（Ohio State University）微生物系和生物化学项目的教授。Strohl博士在中央密歇根大学（Central Michigan University）获得生物学学士学位，在路易斯安那州立大学（Louisiana State University）获得微生物学博士学位。
- William Strohl has served as a member of board of directors since August 2018. In August 2016 Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016 Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013 Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.
- Christina Teng Topsoe
-
Christina Teng Topsoe自2018年8月起担任董事会成员，此前自2013年起担任董事会观察员。自2013年3月起，Tops&248；e女士一直担任Haldor Tops&248；e（一家丹麦催化和化学加工公司）的董事会成员，并自2015年6月起担任其控股公司HTH的董事会成员。Tops&248；e女士此前是Allen&Overy LLP和Simpson Thacher and Bartlett LLP的律师。Tops&248；e女士在哥本哈根大学（University of Copenhagen）获得中国文学学士学位，在北京大学（Peking University）学习中国语言文学，并获得法学学士学位。the University of London的工商管理硕士学位，以及London Business School和Columbia Business School的工商管理硕士学位。
Christina Teng Topsoe has served as a member of board of directors since August 2018 and previously served as an observer on board of directors beginning in 2013. Since March 2013 Ms. Topsoe has served on the board of directors of Haldor Topsoe a Danish catalysis and chemical processing company, and has served on the board of directors of HTH, its holding company, since June 2015. Ms. Topsoe previously was a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsoe pursued a B.A. in Chinese Studies from the University of Copenhagen, studied Chinese Language and Literature at Peking University, and received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School. - Christina Teng Topsoe自2018年8月起担任董事会成员，此前自2013年起担任董事会观察员。自2013年3月起，Tops&248；e女士一直担任Haldor Tops&248；e（一家丹麦催化和化学加工公司）的董事会成员，并自2015年6月起担任其控股公司HTH的董事会成员。Tops&248；e女士此前是Allen&Overy LLP和Simpson Thacher and Bartlett LLP的律师。Tops&248；e女士在哥本哈根大学（University of Copenhagen）获得中国文学学士学位，在北京大学（Peking University）学习中国语言文学，并获得法学学士学位。the University of London的工商管理硕士学位，以及London Business School和Columbia Business School的工商管理硕士学位。
- Christina Teng Topsoe has served as a member of board of directors since August 2018 and previously served as an observer on board of directors beginning in 2013. Since March 2013 Ms. Topsoe has served on the board of directors of Haldor Topsoe a Danish catalysis and chemical processing company, and has served on the board of directors of HTH, its holding company, since June 2015. Ms. Topsoe previously was a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsoe pursued a B.A. in Chinese Studies from the University of Copenhagen, studied Chinese Language and Literature at Peking University, and received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School.
- Jakob Haldor Topsoe
-
Jakob Haldor Topsoe自2018年8月以来一直担任我们的董事会成员。自2015年6月起，Tops&248；e先生一直担任HTH的董事会主席，并自2010年10月起担任其子公司Haldor Tops&248；e的董事会成员，自2016年8月起担任其副主席。自2009年1月起，Tops&248；e先生一直担任丹麦投资管理公司Ambrox Capital的合伙人，并自2016年9月起担任副合伙人。从1996年到2008年，Tops&248；e先生受聘于Alfred Berg/ABN AMRO Bank的多个职位，包括丹麦股票主管。Tops&248；e先生目前担任丹麦海洋运输服务提供商MotorTramp和丹麦慈善基金会Dampskibsselskabet Orients Fond的董事会成员。Tops&248；e先生在哥本哈根商学院（Copenhagen Business School）获得工商管理金融学研究生文凭。
Jakob Haldor Topsoe has served as a member of board of directors since August 2018. Since June 2015 Mr. Topsoe has served as Chairman of the board of directors of HTH, and has served on the board of directors of Haldor Topsoe, its subsidiary, since October 2010 and as its Vice Chairman since August 2016. Since January 2009 Mr. Topsoe has served as Partner at AMBROX Capital, a Danish investment management firm, and as Associate Partner since September 2016. From 1996 to 2008 Mr. Topsoe was employed in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsoe currently serves as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation. - Jakob Haldor Topsoe自2018年8月以来一直担任我们的董事会成员。自2015年6月起，Tops&248；e先生一直担任HTH的董事会主席，并自2010年10月起担任其子公司Haldor Tops&248；e的董事会成员，自2016年8月起担任其副主席。自2009年1月起，Tops&248；e先生一直担任丹麦投资管理公司Ambrox Capital的合伙人，并自2016年9月起担任副合伙人。从1996年到2008年，Tops&248；e先生受聘于Alfred Berg/ABN AMRO Bank的多个职位，包括丹麦股票主管。Tops&248；e先生目前担任丹麦海洋运输服务提供商MotorTramp和丹麦慈善基金会Dampskibsselskabet Orients Fond的董事会成员。Tops&248；e先生在哥本哈根商学院（Copenhagen Business School）获得工商管理金融学研究生文凭。
- Jakob Haldor Topsoe has served as a member of board of directors since August 2018. Since June 2015 Mr. Topsoe has served as Chairman of the board of directors of HTH, and has served on the board of directors of Haldor Topsoe, its subsidiary, since October 2010 and as its Vice Chairman since August 2016. Since January 2009 Mr. Topsoe has served as Partner at AMBROX Capital, a Danish investment management firm, and as Associate Partner since September 2016. From 1996 to 2008 Mr. Topsoe was employed in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsoe currently serves as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation.
- Mary Beth Harler
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Felix J. Baker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- M. Kathleen Behrens
-
M. Kathleen Behrens自2019年1月起担任IGM Biosciences公司董事会成员。自2009年12月以来，Behrens博士一直担任独立生命科学顾问和投资者。2012年1月至2014年6月，她担任私营肿瘤服务公司KEW集团的联合创始人、总裁、首席执行官和董事。从1996年到2009年12月，Behrens博士在投资管理和研究公司RS Investments担任过各种职务，包括担任某些风险基金的普通合伙人。在此之前，从1983年至1996年，她担任Robertson Stephens & Co的普通合伙人和董事总经理。自2009年3月起，Behrens博士担任医学研究和药物开发公司Sarepta医疗的董事会成员，自2015年4月起担任董事长，并担任审计委员会主席和研究与开发委员会成员。2019年6月，她被选入伤口护理公司MiMedx Group的董事会，当时她被任命为董事长，并成为合规和伦理委员会的成员。Behrens博士从2009年6月开始担任生物制药公司Amylin Pharmaceuticals的董事会成员，直到2012年将其出售给Bristol-Myers Squibb。她曾于2001年至2009年初担任PCAST总统科技顾问委员会成员，并担任PCAST个性化医疗小组委员会主席。她还曾担任公共市场生物技术证券分析师和风险投资家，专注于医疗保健、技术和相关投资。她还曾担任国家研究委员会科学、技术和经济政策委员会成员，并担任国家风险投资协会主任、主席和主席。Behrens博士在University of California, Davis获得了生物科学学士学位和微生物学博士学位。
M. Kathleen Behrens has served as a member of IGM Biosciences, Inc.'s board of directors since January 2019. Since December 2009 Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014 she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009 Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996 she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009 Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015 as well as chair of its audit committee and a member of its research and development committee. She was elected to the board of MiMedx Group, a wound care company, in June, 2019 at which time she was named Chairwoman and became a member of the compliance and ethics committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President's Council of Advisors on Science and Technology PCAST from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis. - M. Kathleen Behrens自2019年1月起担任IGM Biosciences公司董事会成员。自2009年12月以来，Behrens博士一直担任独立生命科学顾问和投资者。2012年1月至2014年6月，她担任私营肿瘤服务公司KEW集团的联合创始人、总裁、首席执行官和董事。从1996年到2009年12月，Behrens博士在投资管理和研究公司RS Investments担任过各种职务，包括担任某些风险基金的普通合伙人。在此之前，从1983年至1996年，她担任Robertson Stephens & Co的普通合伙人和董事总经理。自2009年3月起，Behrens博士担任医学研究和药物开发公司Sarepta医疗的董事会成员，自2015年4月起担任董事长，并担任审计委员会主席和研究与开发委员会成员。2019年6月，她被选入伤口护理公司MiMedx Group的董事会，当时她被任命为董事长，并成为合规和伦理委员会的成员。Behrens博士从2009年6月开始担任生物制药公司Amylin Pharmaceuticals的董事会成员，直到2012年将其出售给Bristol-Myers Squibb。她曾于2001年至2009年初担任PCAST总统科技顾问委员会成员，并担任PCAST个性化医疗小组委员会主席。她还曾担任公共市场生物技术证券分析师和风险投资家，专注于医疗保健、技术和相关投资。她还曾担任国家研究委员会科学、技术和经济政策委员会成员，并担任国家风险投资协会主任、主席和主席。Behrens博士在University of California, Davis获得了生物科学学士学位和微生物学博士学位。
- M. Kathleen Behrens has served as a member of IGM Biosciences, Inc.'s board of directors since January 2019. Since December 2009 Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014 she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009 Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996 she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009 Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015 as well as chair of its audit committee and a member of its research and development committee. She was elected to the board of MiMedx Group, a wound care company, in June, 2019 at which time she was named Chairwoman and became a member of the compliance and ethics committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President's Council of Advisors on Science and Technology PCAST from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.
- Julie Hambleton
-
Julie Hambleton，自2021年3月起在Erasca，Inc.董事会任职。2020年8月至2021年3月，汉布尔顿博士担任私营生物技术公司Arch Therapeutics，Inc.的临时总裁兼首席执行官。从2018年6月到2020年4月退休，汉布尔顿博士在肿瘤医药公司IDEAYA生物科学公司担任高级副总裁、首席医疗官、开发主管。2017年9月至2018年5月，2016年3月至2016年5月，汉布尔顿博士担任多家生命科学公司的独立战略顾问。2016年5月至2017年9月，她在全球生物制药公司百时美施贵宝担任副总裁兼美国医疗主管。2015年8月至2016年2月，汉布尔顿博士在生物技术公司Five Prime Therapeutics担任执行副总裁兼首席医疗官，并于2012年12月至2015年8月担任高级副总裁兼首席医疗官。从2010年4月到2012年11月，汉布尔顿博士在Clovis肿瘤药物担任临床开发副总裁。从2003年到2010年，汉布尔顿博士在基因泰克的生物肿瘤学领域担任越来越重要的职务。汉布尔顿博士在两家上市生物技术公司的董事会任职：IGM Biosciences，Inc.，自2018年8月起；SpringWorks Therapeutics，Inc.，自2020年5月起。汉布尔顿博士在加州大学旧金山分校完成了血液肿瘤学培训，随后她于1993年至2003年在该学院任职。汉布尔顿博士拥有杜克大学的护理学士学位和凯斯西储大学医学院的医学博士学位，并获得血液学和内科医学的董事会认证。
Julie Hambleton has served on Erasca, Inc. board of directors since March 2021. From August 2020 to March 2021 Dr. Hambleton served as interim President and Chief Executive Officer of Arch Therapeutics, Inc., a private biotechnology company. From June 2018 to April 2020 when she retired, Dr. Hambleton was Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, Inc., an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016 Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017 she served as Vice President, Head US Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016 Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012 Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010 Dr. Hambleton held roles of increasing responsibility in BioOncology at Genentech. Dr. Hambleton serves on the boards of two publicy-traded biotechnology companies: IGM Biosciences, Inc., since August 2018 and SpringWorks Therapeutics, Inc., since May 2020. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton holds a B.S. in nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and is board-certified in hematology and internal medicine. - Julie Hambleton，自2021年3月起在Erasca，Inc.董事会任职。2020年8月至2021年3月，汉布尔顿博士担任私营生物技术公司Arch Therapeutics，Inc.的临时总裁兼首席执行官。从2018年6月到2020年4月退休，汉布尔顿博士在肿瘤医药公司IDEAYA生物科学公司担任高级副总裁、首席医疗官、开发主管。2017年9月至2018年5月，2016年3月至2016年5月，汉布尔顿博士担任多家生命科学公司的独立战略顾问。2016年5月至2017年9月，她在全球生物制药公司百时美施贵宝担任副总裁兼美国医疗主管。2015年8月至2016年2月，汉布尔顿博士在生物技术公司Five Prime Therapeutics担任执行副总裁兼首席医疗官，并于2012年12月至2015年8月担任高级副总裁兼首席医疗官。从2010年4月到2012年11月，汉布尔顿博士在Clovis肿瘤药物担任临床开发副总裁。从2003年到2010年，汉布尔顿博士在基因泰克的生物肿瘤学领域担任越来越重要的职务。汉布尔顿博士在两家上市生物技术公司的董事会任职：IGM Biosciences，Inc.，自2018年8月起；SpringWorks Therapeutics，Inc.，自2020年5月起。汉布尔顿博士在加州大学旧金山分校完成了血液肿瘤学培训，随后她于1993年至2003年在该学院任职。汉布尔顿博士拥有杜克大学的护理学士学位和凯斯西储大学医学院的医学博士学位，并获得血液学和内科医学的董事会认证。
- Julie Hambleton has served on Erasca, Inc. board of directors since March 2021. From August 2020 to March 2021 Dr. Hambleton served as interim President and Chief Executive Officer of Arch Therapeutics, Inc., a private biotechnology company. From June 2018 to April 2020 when she retired, Dr. Hambleton was Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, Inc., an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016 Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017 she served as Vice President, Head US Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016 Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012 Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010 Dr. Hambleton held roles of increasing responsibility in BioOncology at Genentech. Dr. Hambleton serves on the boards of two publicy-traded biotechnology companies: IGM Biosciences, Inc., since August 2018 and SpringWorks Therapeutics, Inc., since May 2020. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton holds a B.S. in nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and is board-certified in hematology and internal medicine.
高管简历
中英对照 | 中文 | 英文- Mary Beth Harler
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介